Statin therapy is associated with improved survival in patients with non-serous-papillary epithelial ovarian cancer: a retrospective cohort analysis

Autor: S. Diane Yamada, Lacey M. Litchfield, Mohammed Habis, Michael J. Bradaric, Nadia Ismail, Ernst Lengyel, Kristen Wroblewski, Iris L. Romero
Jazyk: angličtina
Rok vydání: 2014
Předmět:
Oncology
endocrine system diseases
Epidemiology
Cancer Treatment
lcsh:Medicine
Pathology and Laboratory Medicine
Cohort Studies
Hyperlipidemia
Basic Cancer Research
Drug Discovery
Medicine and Health Sciences
lcsh:Science
Ovarian Neoplasms
Likelihood Functions
Multidisciplinary
Cancer Drug Discovery
Pharmaceutics
Cancer Risk Factors
Confounding
Endocrine Therapy
3. Good health
Ovarian Cancer
Nutritional Correlates of Cancer
Cohort
Cancer Therapy
Female
Lovastatin
Cancer Epidemiology
medicine.drug
Cohort study
Research Article
medicine.medical_specialty
Drug Research and Development
Hyperlipidemias
Disease-Free Survival
Signs and Symptoms
Drug Therapy
Diabetes mellitus
Internal medicine
medicine
Humans
cardiovascular diseases
Cell Proliferation
Retrospective Studies
Pharmacology
business.industry
lcsh:R
Cancers and Neoplasms
nutritional and metabolic diseases
Retrospective cohort study
medicine.disease
Surgery
lcsh:Q
Hydroxymethylglutaryl-CoA Reductase Inhibitors
business
Ovarian cancer
Gynecological Tumors
Zdroj: PLoS ONE, Vol 9, Iss 8, p e104521 (2014)
PLoS ONE
ISSN: 1932-6203
Popis: Aim To determine whether statin use is associated with improved epithelial ovarian cancer (OvCa) survival. Methods This is a single-institution retrospective cohort review of patients treated for OvCa between 1992 and 2013. Inclusion criteria were International Federation of Gynecology and Obstetrics (FIGO) stage I–IV OvCa. The primary exposures analyzed were hyperlipidemia and statin use. The primary outcomes were progression-free survival (PFS) and disease-specific survival (DSS). Results 442 patients met inclusion criteria. The cohort was divided into three groups: patients with hyperlipidemia who used statins (n = 68), patients with hyperlipidemia who did not use statins (n = 28), and patients without hyperlipidemia (n = 346). OvCa outcomes were evaluated. When we analyzed the entire cohort, we found no significant differences in PFS or DSS among the groups. The median PFS for hyperlipidemics using statins, hyperlipidemics not using statins, and non-hyperlipidemics was 21.7, 13.6, and 14.7 months, respectively (p = 0.69). Median DSS for hyperlipidemics using statins, hyperlipidemics not using statins, and non-hyperlipidemics was 44.2, 75.7, and 41.5 months, respectively (p = 0.43). These findings did not change after controlling for confounders. However, a secondary analysis revealed that, among patients with non-serous-papillary subtypes of OvCa, statin use was associated with a decrease in hazards of both disease recurrence (adjusted HR = 0.23, p = 0.02) and disease-specific death (adjusted HR = 0.23, p = 0.04). To augment the findings in the retrospective cohort, the histology-specific effects of statins were also evaluated in vitro using proliferation assays. Here, statin treatment of cell lines resulted in a variable level of cytotoxicity. Conclusion Statin use among patients with non-serous-papillary OvCa was associated with improvement in both PFS and DSS.
Databáze: OpenAIRE
Externí odkaz: